Science & Enterprise subscription

Follow us on Twitter

  • Results from a large-scale clinical trial show almost the same health outcomes for patients prescribed high or low… https://t.co/cAg7Ygkv3I
    about 20 hours ago
  • New post on Science and Enterprise: Trial Shows Same High/Low Dose Aspirin Outcomes https://t.co/N8mjm3cWX8 #Science #Business
    about 20 hours ago
  • Venture funding for start-ups providing artificial intelligence services in health care climbed to a record high vo… https://t.co/FHzRPWsgKR
    about 3 days ago
  • New post on Science and Enterprise: Infographic – Health Care A.I. Funds Jump in Q1 https://t.co/4L1DrqPRFT #Science #Business
    about 3 days ago
  • This New York Times essay got here just in time ... Your Car, Toaster, Even Washing Machine, Can’t Work Without The… https://t.co/cuRLpV3PIT
    about 3 days ago

Please share Science & Enterprise

ImmunoGen, Novartis to Collaborate on Cancer Drugs

Drug vials (Hey Paul/Flickr)ImmunoGen Inc., a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis, a pharmaceutical manufacturer headquartered in Basel, Switzerland.

Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for exclusive rights to use the company’s Targeted Antibody Payload (TAP) technology with antibodies to the antigen targets specified by Novartis. ImmunoGen says a TAP compound consists of a tumor-targeting manufactured antibody with a cancer-killing agent attached as a payload. The antibody delivers the payload specifically to tumor cells. Seven TAP compounds are now in clinical testing, either through ImmunoGen’s own product programs and those of its partners.

The agreement also provides that for each target resulting in an anticancer therapeutic, ImmunoGen is entitled to receive milestone payments potentially totaling $200.5 million plus royalties on any product sales. ImmuGen also will also be compensated for research and any manufacturing done on behalf of Novartis.

Related: Novartis to Develop Flu Vaccines with Synthetic Genomics

Photo: Hey Paul/Flickr

Comments are closed.